FDA Determines Regulatory Review Period for MYCAMINE New Drug Application

Summary

The US Food and Drug Administration (FDA) has officially confirmed the review period for MYCAMINE's new drug application, following a request from the patent extension office, as required by law. This decision was made due to the submission of patent extension applications by the patent office, Department of Commerce, for the extension of patents claiming the human drug product MYCAMINE.